Bhuvaneswari Ramaswamy MD

Bhuvaneswari Ramaswamy MD
Asst ProfessorCollege of Medicineramaswamy.8@osu.edu
B401A Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-0066Fax: (614) 293-7529
  • Translational Therapeutics

Research Description

As a clinical researcher in Hematology/Oncology, Dr. Ramaswamy is investigating new methods to identify which breast tumors are resistant to hormone therapy. By understanding what makes theses tumors resistant, researchers may be able to develop alternative therapies. For example, scientists might be able to develop a co-agent that would increase the ability of these tumors to respond to hormone therapies.

Current Publications

  • Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CLPhase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer.Clin Breast Cancer 14 228-34 8/1/2014
  • Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers S, Puhalla S, Shapiro CL, Ramaswamy BA Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.Invest New Drugs in press 6/5/2014
  • Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae ER, Wesolowski R, Layman RM, Mrozek E, Pan X, Summers TA, Shapiro CL, Chalmers JJ, Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa AHeterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.Breast Cancer Res 16 R23 1/1/2014
  • Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E, Wesolowski RDocetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.Support Care Cancer 21 2679-86 10/1/2013
  • Wenzell CM, Berger MJ, Blazer MA, Crawford BS, Griffith NL, Wesolowski R, Lustberg MB, Phillips GS, Ramaswamy B, Mrozek E, Flynn JM, Shapiro CL, Layman RMPilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.Support Care Cancer 21 2845-51 10/1/2013
  • Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CLSevere and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.Cancer Chemother Pharmacol 71 1183-90 5/1/2013
  • Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161 156-64 3/1/2013
  • Singh R, Ramaswamy B, Hazarika MJuvenile aggressive cemento-ossifying fibroma of the sphenoid sinus with proptosis: a surgical dilemma.BMJ Case Rep 2013 1/1/2013
  • Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder SHedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.Cancer Res 72 5048-59 10/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu